Genetraks raises $6m
Wednesday, 18 December, 2002
Genetraks, a start-up biotech developing blood tests for use in pre-race evaluation of animals such as racehorses, has received a $6 million injection of venture capital.
The commercial potential of its technology for assessing the health of racing animals with a view to maximising their performance has helped the company win investment interest in a difficult market.
The Brisbane company, which received earlier support from St George Innovation Fund and a $246,380 Biotechnology Innovation Fund (BIF) grant, is based on bioinformatics techniques. Its technology relates to the diagnostic capacity of gene expression 'signatures' in white blood cells in immune-mediated diseases.
The company is led by two veterinary PhDs, Rosalyn and Richard Brandon, who respectively are its CEO and biotechnology director.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
